Skip to main content

Table 2 Change in BCVA at each time point following transition to aflibercept therapy

From: Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab

Time point BCVAa
(Mean ± SD)
Change from Baseline
(Mean ± SD)
Change from Baseline
(%)
P-valueb 95% CI
Lower Upper
Baseline 0.45 ± 0.28      
Month 1 0.4 ± 0.27 − 0.05 ± 0.13 6 0.01 − 0.09 -0.01
Month 3 0.41 ± 0.31 − 0.04 ± 0.16 11 0.079 − 0.08 0.01
Month 6 0.44 ± 0.35 − 0.01 ± 0.22   0.929 − 0.07 0.05
Month 12 0.47 ± 0.39 0.02 ± 0.28 7 1.00 0.06 0.1
  1. BCVA best-corrected visual acuity, CI confidence interval
  2. alogMAR, log10 of reciprocal of Snellen visual acuity
  3. b Based on hybrid linear mixed model, adjusted for multiple comparisons based on Sidak method